Pharmaceuticals

SEELOS THERAPEUTICS INC

Seelos Therapeutics Inc. released FY2023 cumulative Q3 earnings on August 14, 2024 (EST), with actual revenue of 1.55M USD and EPS of -1.761K

Seelos Therapeutics Inc. released FY2024 H1 earnings on August 14, 2024 (EST) with actual revenue of 955K USD and EPS of -7.3872

Seelos Therapeutics Inc. released FY2023 H1 earnings on August 14, 2024 (EST), with actual revenue of 1.144 M USD and EPS of -1.348 K USD

Seelos Therapeutics Inc. released FY2023 Q1 earnings on May 14, 2024 (EST), with actual revenue of 808 K USD and EPS of -458.2707

Seelos Therapeutics Inc. released FY2024 Q1 earnings on May 14, 2024 (EST), with actual revenue of 579 K USD and EPS of -26.2147

Seelos Therapeutics Inc. released FY2023 annual earnings on March 6, 2024 (EST), with actual revenue of 2.203 M USD and EPS of -989.5253

Seelos Therapeutics Inc. released FY2022 earnings on March 6, 2024 (EST), with actual revenue of 0 USD and EPS of -2654.72

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

SEELQ

SEEL

ARKG

LABU

Seaport Therapeutics (SPTX), a Boston-based biotech, has increased its IPO size to 14.16 million shares, priced at $18.00, raising $254.88 million. The shares will begin trading on NASDAQ on May 1, 2026. The company plans to use the proceeds for Phase 2 clinical trials of its drugs for major depression. At pricing, Seaport Therapeutics has a market cap of $954.5 million. Goldman Sachs and others are the joint book-runners for the IPO.

IPO Scoop

Seelos Therapeutics

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Goldman Sachs

JPMorgan Chase

Citigroup

Stifel Financial

Nasdaq

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range

Seaport Therapeutics, Inc. has priced its upsized IPO of 14.16 million shares at $18 each, raising approximately $254.9 million. The shares will trade on the Nasdaq under the ticker "SPTX" starting May 1, 2026, with the offering closing on May 4, 2026. Underwriters have a 30-day option to purchase an additional 2.12 million shares, with Goldman Sachs, J.P. Morgan, and others as joint book-running managers.

rttnews

Proshares UltraShort Nasdaq Biotech

Minsheng Royal CSI Biotechnology Theme ETF

Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each

588130

512170

512290

516500

On April 29, 2026, Avalyn Pharma Inc. announced the pricing of its upsized initial public offering, consisting of 16,666,667 shares priced at $18.00 each, aiming for gross proceeds of approximately $300 million. The company is offering all shares and has granted underwriters a 30-day option to purchase an additional 2,500,000 shares at the IPO price, net of discounts and commissions.

Fidelity

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP CSI Medical Service ETF

VG Health

Guotai CSI Bio-medicine ETF

iShares US Pharma

ChinaAMC CSI Biotechnology Theme ETF

Morgan Stanley

Jefferies Financial

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Avalyn Announces Pricing of Upsized Initial Public Offering

426CVR015TMP

COEP

NBSE.ESC

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Hepion Pharmaceuticals, Inc.

Coeptis Therapeutics

ESC NEUBASE THERAPEUTI

Seaport ENT

Seaport and Hemab target $180m IPOs as biotech listings accumulate

HELP

ATAI

DFTX

CMPS

PSIL

President Trump has signed an executive order to ease research restrictions on psychedelic medicine, inspired by a text from podcaster Joe Rogan. This move aims to legitimize an industry hindered by federal regulations since the 1970s. The order directs federal agencies to facilitate access to experimental treatments for terminally ill patients and allocates $50 million for state-level research into ibogaine. Advocates express cautious optimism about potential mental health benefits, although widespread access remains uncertain without further action. The FDA will also expedite approval processes for promising psychedelic therapies.

SEELOS THERAPEUTICS INC(SEELQ.US)

The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range

Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each

Avalyn Announces Pricing of Upsized Initial Public Offering

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Trump’s Rogan-inspired psychedelics order stokes cautious optimism